DAGYNIL 1.25mg price in UAE

Overview

Welcome to Dwaey, specifically on DAGYNIL 1.25mg Tablets page.
This medicine contains an important and useful components, as it consists of Oestrogens (conjugated).
DAGYNIL 1.25mg is available in the market in concentration 1.25mg/Tablet and in the form of Tablets.

DAGRA PHARMACEUTICALS is the producer of DAGYNIL 1.25mg and it is imported from NETHERLANDS, The most popular alternatives of DAGYNIL 1.25mg are listed downward .

Mode Of Action

Aceclofenac, a phenylacetic acid derivative, has antiinflammatory and analgesic properties. It is a potent inhibitor of cyclo-oxygenase which is involved in the production of prostaglandins.

Indication

Indicated for the relief of pain and inflammation in both acute and chronic pain like osteoarthritis
rheumatoid arthritis
ankylosing spondylitis
dental pain
post-traumatic pain
low back pain
gynaecological pain etc.

Precaution

Cautiously administer to patients with GI disease, ulcerative colitis, Crohn's disease, haematological abnormalities, hepatic porphyria; history of bronchial asthma; history of heart failure or hypertension; mild renal, hepatic or cardiac impairment. May impair ability to drive or operate machinery. Elderly. Patients suffering from severe hepatic impairment must be monitored.

Side Effects

Gastrointestinal disorders (dyspepsia
abdominal pain
nausea and diarrhoea) and occasional occurance of dizziness. Dermatological side effects including pruritus and rash. Abnormal hepatic enzyme levels and raised serum creatinine have occasionally been reported. Potentially Fatal: Severe GI bleeding; nephrotoxicity; blood dyscrasias.

Contra indication

Hypersensitivity to aspirin or NSAIDs; moderate to severe renal impairment; pregnancy (3rd trimester); history of peptic ulceration or GI bleed; patients with infections.

Pregnancy and lactation

Interaction

May increase plasma concentrations of lithium and digoxin. Increased nephrotoxicity when used with diuretics or ciclosporin. Monitor serum potassium when used with potassium-sparing diuretics and ACE inhibitors. May enhance activity of anticoagulants. May increase risk of methotrexate toxicity when administered within 24 hr of methotrexate admin. Increased risk of GI bleed with other NSAIDs. Increased risk of convulsion with quinolones.